Noxopharm has announced promising new data in support of a future human trial for SOF-SKN™, the company’s cutaneous lupus drug candidate, confirming several important characteristics of the drug and representing a positive step in its refinement.

Read more here: www.noxopharm.com/pdf/a094654d...

Noxopharm is pleased to announce the appointment of Dr Olivier Laczka as its new Chief Executive Officer with immediate effect. Dr Laczka has been the driving force behind company’s promising Sofra™ platform for the past several years.
Read the announcement here: www.noxopharm.com/pdf/52caff1f...

New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules - Biweekly newsletter of The Cytokine Society A study from the Gantier lab (Hudson Institute/Monash University), published in Nature Immunology, reveals that naturally occurring 2′-O-methyl-guanosine RNA fragments act as potent antagonists of TLR7 and TLR8, binding a previously unknown site to keep the receptors in an inactive state.

New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules signals.cytokinesociety.org/2026/03/14/g...

Noxopharm has received a $2,806,583.03 rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2025.

Read more here: www.noxopharm.com/pdf/e2e613a6...

Noxopharm (ASX:NOX) has signed a $5 million At-the-Market equity deal with Acuity Capital, securing flexible standby funding through 2031 with full discretion on share issuance and pricing. www.noxopharm.com/pdf/647ad621...

Professor Michael Gantier is the lead author on the paper, which involved several teams of national and international researchers.

Noxopharm and @hudsonresearch.bsky.social announce a breakthrough scientific paper regarding the Sofra™ platform in top-ranking journal Nature Immunology.

Read the full announcement here: www.noxopharm.com/pdf/e17f82ba...

Noxopharm’s latest quarterly is now out, covering more external interest in the company’s Sofra platform and the recent successful conclusion of the HERACLES clinical trial.

Read more here: www.noxopharm.com/pdf/35e7336f...

Noxopharm announces the final cohort of SOF-SKN™ has been completed in the HERACLES trial.

The clinical part of the trial has now successfully concluded, with a highly positive safety outcome for all dosing groups.

Read more here: www.noxopharm.com/pdf/70fe930c...

The Future of mRNA Is Being Built in APAC The Future of mRNA Is Being Built in APAC

To start the year, Noxopharm CEO Dr Gisela Mautner is featured in a great article from BioSpectrum Asia on why mRNA technology represents a huge opportunity for the APAC region.

www.biospectrumasia.com/analysis/29/...

Noxopharm has announced the first multiple-dose cohort of SOF-SKN™ has been successfully completed in the HERACLES trial.

The Safety Steering Committee determined the treatment to be safe and well tolerated, with no clinically relevant issues found.

More here: www.noxopharm.com/pdf/239710c2...

Noxopharm has released its 2025 AGM presentation covering inflammation’s links to numerous diseases, HERACLES clinical trial progress, external interest, market opportunities and catalysts, and SOF-SKN™ advantages in a global market.
Read more here: www.noxopharm.com/pdf/f67956fe...

Noxopharm has announced the first dosing has been administered in the second part of the HERACLES clinical trial.

This second part of the trial involves multiple doses of SOF-SKN being given to two cohorts in succession.

Read more here: www.noxopharm.com/pdf/ddeef22f...

Noxopharm announces the awarding of a TechVoucher grant for a joint project with UNSW Sydney, who will use the funding to explore how Noxopharm’s novel anti-inflammatory oligonucleotides could be used to reduce the inflammation caused by implants.

Read more here: www.noxopharm.com/pdf/8263eb2b...

Disease of 1,000 faces shows how science is tackling immunity’s dark side It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect as many as 50 million Americans and millions more worldwide.

Lupus can have severe effects on people's lives and can be hard to diagnose - read more about the disease and the latest global research in the article below.

apnews.com/article/auto... 
Disease of 1,000 faces shows how science is tackling immunity’s dark side

Noxopharm announces the start of the HERACLES clinical trial Part II, following successful single-dose testing. Multiple doses of ascending concentrations of SOF-SKN will continue safety testing at a more intensive level over a longer period of time. More here: www.noxopharm.com/pdf/1126c863...

The latest quarterly is now out, with news that Noxopharm has signed several collaboration agreements with Australian and international academic and research institutions.

Read more here: www.noxopharm.com/pdf/07c5e9d5...

World-First RNA Trial A Breakthrough For Lupus Patients Melbourne researchers have developed a new RNA drug designed to prevent the damaging effects of the debilitating autoimmune disease lupus, in a major breakthrough supported by the Allan Labor Governme...

Great to see the Victorian Government supporting @hudsonresearch.bsky.social and Noxopharm's work taking our innovative SOF-SKN drug to a clinical trial and offering hope to people with lupus.

www.premier.vic.gov.au/world-first-...

Noxopharm has announced it has been granted its first US patent for the Sofra™ technology platform.

It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers.

Read more here: www.noxopharm.com/pdf/96da7dc3...

Nobel Prize in Physiology or Medicine 2025 The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"

The immune system is centre stage once again as this year's Nobel Prize in Physiology or Medicine is awarded for groundbreaking discoveries concerning peripheral immune tolerance.

www.nobelprize.org/prizes/medic...

Biocurious: Noxopharm has the 'burning fire' of inflammation squarely in its sights - Stockhead After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin lupus.

Check out the company's latest media coverage on Stockhead.

Noxopharm has the 'burning fire' of inflammation squarely in its sights: stockhead.com.au/health/biocu...

Noxopharm announces the fourth and last single-dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial.

Read more here: www.noxopharm.com/pdf/e50f60a8...

Noxopharm has released a new Sofra™ presentation that includes an overview of the technology platform, global autoimmune disease therapeutics and cutaneous lupus market info, SOF-SKN advantages, and numerous catalysts.

Read it here: www.noxopharm.com/pdf/a11601fa...

Noxopharm announces the third dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. The fourth cohort will now receive the highest dose approved for this trial.

Read more here: www.noxopharm.com/pdf/42f7ce25...

Noxopharm is very proud to have been nominated as a finalist in this year's Health Industry Hub awards, which celebrate change-makers across the industry.

Read more about all the categories and finalists here: www.healthindustryhub.com.au/health-indus...

Noxopharm announces the second dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the third cohort of participants, who will receive a higher dose.

Read more here: www.noxopharm.com/pdf/51866b0a...

Noxopharm has announced initial results from US company Tezcat Biosciences testing assets from the Sofra™ technology platform.

Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes.

Read more here: www.noxopharm.com/pdf/6d742ee9...

Noxopharm has expanded the scope of its existing collaborations with three companies following the signing of Material Transfer Agreements several months previously. Read more news in the latest quarterly here: www.noxopharm.com/pdf/65a545cf...

Noxopharm CEO Dr Gisela Mautner has featured as a panelist at Bio Connections Australia this week. The panel of accomplished female leaders discussed the role of women in the industry and how biotech companies can attract and retain more women in executive and scientific roles.

Noxopharm announces the first dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the second cohort of participants, who will receive a higher dose.

Read more here: www.noxopharm.com/pdf/8dbd34b1...